BTIG analyst Mark Massaro maintained a Buy rating on Alpha Teknova (TKNO – Research Report) on January 5 and set a price target of $3.50. The company’s shares closed last Friday at $3.58.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS. According to TipRanks, Massaro has an average return of -16.0% and a 30.80% success rate on recommended stocks.
Currently, the analyst consensus on Alpha Teknova is a Moderate Buy with an average price target of $4.75.
See Insiders’ Hot Stocks on TipRanks >>
TKNO market cap is currently $145.8M and has a P/E ratio of -2.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpha Teknova (TKNO) Company Description:
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Read More on TKNO:
